|
Other articles:
|
www.researchgate.net/. /259395483_Bruton's_Tyrosine_Kinase_(BTK)_ Inhibitors_in_Clinical_TrialsABSTRACT BTK is a cytoplasmic, non-receptor tyrosine kinase that transmits
https://www.celgene.com/research-development/. /kinase-inhibitors/CachedSimilarBtk plays a critical role in the development and activation of B cells, and its
www.sciencedirect.com/science/article/pii/S8756328213004870SimilarHighlights. •. Btk inhibitor ibrutinib suppresses osteoclastogenesis by inhibiting
www.dovepress.com/getfile.php?fileID=15399CachedSimilarPreclinical and early clinical results indicate that Btk inhibitors may be useful .
meetinglibrary.asco.org/content/98688-114CachedSimilarA phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765
www.science.gov/topicpages/i/irreversible+btk+inhibitor.htmlSimilarIbrutinib, a novel first-in-human BTK-inhibitor, has demonstrated clinical
www.pnas.org/content/107/29/13075.fullJul 20, 2010 . Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is
www.healio.com/. /ibrutinib-btk-inhibitor-offers-hope-to-patients-with-b-cell -malignanciesCachedBruton's tyrosine kinase (BTK) is one of the critical enzymes in the BCR pathway
www.oncologypractice.com/. /btk-inhibitor. / df3801ec11a05ab6945f1a9d211a539b.htmlCachedOct 23, 2013 . Bruton's tyrosine kinase (BTK) is a critical component of B-cell–receptor signaling
pubs.acs.org/doi/abs/10.1021/jm500305pApr 8, 2014 . Structure-based drug design was used to guide the optimization of a series of
www.aegera.com/preclinical_programs.phpCachedSimilarSmall Molecule BTK Kinase Inhibitors. As part of a novel kinase inhibitor platform
depts.washington.edu/hemeweb/. /Shiovitz%20slides%209-13-13.pdfCachedSimilarSep 13, 2013 . Overview. • CLL/SLL o Overview o Current therapies. • BTK-inhibitors in CLL. •
www.axonmedchem.com/product/2018cgi1746.htmlCachedSimilarBiological Activity: Potent and highly selective inhibitor of Bruton's tyrosine kinase
www.principiabio.com/pipeline/btk-inhibitor/CachedPRN1008: BTK inhibitor. Highly differentiated, first in class opportunity in
www.discoverx.com/. /to-b-or-not-to-b-phenotypic-profiling-btk-inhibitoCachedHere, we present BioMAP® analysis of two BTK inhibitors revealing cell-
www.bloodjournal.org/content/122/21/4397ONO-4059 is a highly potent and selective oral Btk inhibitor with an IC50 in the
www.ncbi.nlm.nih.gov/pubmed/23296407SimilarIbrutinib is a potent covalent kinase inhibitor that targets BTK. BTK, or Bruton's
https://ash.confex.com/ash/2012/webprogram/Paper53069.htmlCachedSimilar189 The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes
www.hematology.org/Thehematologist/Mini-Review/1067.aspxCachedMay 1, 2013 . Small molecule inhibitors of kinases that participate in BCR signaling pathways,
www.onclive.com/. /Success-of-First-BTK-Inhibitor-Opens-New-Options-in- B-Cell-MalignanciesCachedSimilarMar 3, 2014 . In the past few years, overwhelmingly positive results have been observed with
en.wikipedia.org/wiki/IbrutinibCachedSimilarIt is an orally-administered, selective and covalent inhibitor of the enzyme
www.jhoonline.org/content/6/1/59CachedSimilarAug 19, 2013 . Ibrutinib, a novel first-in-human BTK-inhibitor, has demonstrated clinical
www.nature.com/nbt/journal/v32/n9/full/nbt0914-852a.htmlSep 9, 2014 . Pharmacyclics first-in-class BTK inhibitor Imbruvica (ibrutinib) received expanded
www.selleckchem.com/pathways_btk.htmlCachedOur Btk inhibitors are novel, potent and selective with many product citations and
www.cellagentech.com/PCI-32765-Ibrutinib/CachedSimilarPCI-32765 (Ibrutinib) is a selective and irreversible pyrrolopyrimidine-based
www.medkoo.com/Anticancer-library/BTK-inhibitor.htmCachedBTK inhibitors. Targeting Bruton's tyrosine kinase (BTK) with a small molecule
jpet.aspetjournals.org/content/338/1/154.fullSimilarGDC-0834 inhibited BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical
clinicaltrials.gov/show/NCT02029443CachedSimilarJan 6, 2014 . This study is evaluating the safety and efficacy of a new Bruton tyrosine kinase (
www.lymphomation.org/btk-inhibitors.htmCachedSimilarMar 23, 2014 . Agents that Target Disease Pathways > BtK Inhibitors . As we understand it,
www.ncbi.nlm.nih.gov/pubmed/24556163SimilarACS Chem Biol. 2014 May 16;9(5):1086-91. doi: 10.1021/cb4008524. Epub
www.tocris.com/dispprod.php?ItemId=2296CachedSimilarBiological Activity. Potent and selective inhibitor of Bruton's tyrosine kinase (BTK).
ard.bmj.com/content/early/2014/04/23/annrheumdis-2013-204143.fullApr 24, 2014 . The effects of a Btk-specific inhibitor, RN486, on gene expression in human
https://www.evaluategroup.com/View/. /btk_inhibitor_programCachedProduct profile for BTK Inhibitor Program. Includes latest news and historic
mct.aacrjournals.org/content/12/11_Supplement/C258.shortAbstract. Ibrutinib is a BTK (Bruton tyrosine kinase) targeting inhibitor that has
www.jimmunol.org/content/193/1/185.abstractJul 1, 2014 . Abstract. Inhibitors of Bruton's tyrosine kinase (BTK) possess much promise for
www.nature.com/leu/journal/v28/n3/full/leu2013358a.htmlSimilarDec 13, 2013 . Ibrutinib, a BTK inhibitor, has demonstrated a significant clinical activity against
www.researchtopractice.com/5MJCASH2014/5/10CachedMay 10, 2014 . Treon SP et al. A prospective multicenter study of the Bruton's tyrosine kinase
healthcare.blogs.ihs.com/. /btk-inhibitors-pointing-the-way-to-the-future-of- targeted-therapies/CachedSimilarMay 8, 2012 . Tolero Pharma is the third drug firm in a matter of months to make a decisive
www.bioinvest.com/pcyc-introducing-the-autoimmune-program-the-next- chapter/CachedSimilarFeb 20, 2014 . Moreover, after an exhaustive look back at BTK inhibition in autoimmune
www.targetedonc.com/. /Dr-Woyach-on-BTK-Inhibition-and-the- Mechanism-of-Action-of-IbrutinibCachedSimilarAug 20, 2013 . Jennifer Woyach, MD, Assistant Professor of Internal Medicine, Division of
journals.lww.com/. /CLL__BTK_Inhibitor_Ibrutinib_Promising_for.9.aspxSimilarJun 25, 2012 . CHICAGO—Bruton's tyrosine kinase (BTK)-inhibitor ibrutinib shows “impressive”
www.biovision.com/btk-inhibitor-cnx-774-8620.htmlCachedCNX-774 is a potent, irreversible BTK inhibitor (IC₅₀ < 1 nM). CNX-774 is highly
pubs.acs.org/doi/abs/10.1021/cb4008524SimilarFeb 20, 2014 . BTK is a member of the TEC family of non-receptor tyrosine kinases whose
www.nejm.org/doi/full/10.1056/NEJMc1402716Jun 12, 2014 . Ibrutinib, an inhibitor that binds covalently to C481 of Bruton's tyrosine kinase (
www.oncodesign.com/. / ONCODESGIN%20Development%20of%20Bruton's%20Tyrosine%. CachedSimilar•ONO-WG-307 is a highly potent and selective, oral Btk inhibitor in development
www.bioworld.com/. /beigene-moves-btk-inhibitor-clinic-inks- manufacturing-deal-biCachedSep 10, 2014 . SHANGHAI – Upstart Beigene Co. Ltd. wowed observers last year when it landed
www.cancer.gov/drugdictionary?cdrid=638648CachedSimilaribrutinib Patient Information An orally bioavailable, small-molecule inhibitor of
www.medscape.com/viewarticle/778397CachedSimilarFeb 5, 2013 . Dr. Bruce Cheson reports on a plethora of data presented at ASH 2012 that
www.pharmacyclics.com/CachedSimilarPipeline. BTK Inhibitor · HDAC Inhibitor · Factor VIIa Inhibitor. Clinical Trials.
Sitemap
|